Skip to content

Yu-Ping Ning

6 papers in the library · 46 citations · publishing 2022-2025

Papers

Sort Most recent Most cited

Intravenous ketamine versus electroconvulsive therapy for major depressive disorder or bipolar depression: A meta-analysis of randomized controlled trials.

Journal of Affective Disorders February 15, 2025 Zhan-Ming Shi, Xian-Jun Lan, Qing Chen et al. 6 citations

Intravenous (IV) ketamine has been evaluated alongside electroconvulsive therapy (ECT) in addressing major depressive disorder (MDD) or bipolar depression (BD), though the comparative outcomes remain inconclusive. This meta-analysis aimed to provide a systematic assessment of the efficacy, safety, and tolerability of IV ketamine relative to ECT for treating MDD or BD. Randomized controlled...

Efficacy and safety of esketamine versus propofol in electroconvulsive therapy for treatment-resistant depression: A randomized, double-blind, controlled, non-inferiority trial.

Journal of Affective Disorders 2025 Qing-Bin Zeng, De-Cheng Zou, Xing-Bing Huang et al. 12 citations

Electroconvulsive therapy (ECT) is a commonly used alternative for treatment-resistant depression (TRD). Although esketamine has a rapid pharmacological antidepressant action, it has not been studied as an ECT anesthetic. The objective of this study was to compare the efficacy and safety of esketamine with propofol when both are used as ECT anesthetic agents. Forty patients with TRD were...

Body mass index is associated with the antidepressant effects of intravenous ketamine in patients with depression.

Frontiers in Psychiatry 2025 Jian-Qiang Tan, Li-Mei Gu, Yan-Ling Zhou et al. 2 citations

We aimed to explore the correlation between baseline body mass index (BMI) and the antidepressant properties of intravenous ketamine in patients with depression. We divided 135 patients diagnosed with either major depressive disorder (n=103) or bipolar depression (n=32) into lower and higher BMI groups based on their baseline BMI. Patients with a lower BMI (BMI0.05). The linear mixed models...

Rapid treatment center for depression in China: constructive reflections and transnational implications.

Frontiers in Psychiatry 2025 Zhan-Ming Shi, Xing-Bing Huang, Yan-Ling Zhou et al. 1 citation

Enhancing the early diagnosis and standardized treatment of major depressive disorder (MDD), as advocated by the National Health Commission of China, is a key priority in the mental health initiatives of the nation. To achieve this, numerous evidence-based rapid treatment centers for MDD have been established or are currently under development across the country. These centers focus on the...

Psilocybin for major depressive disorder: a systematic review of randomized controlled studies

Frontiers in Psychiatry September 23, 2024 Zhan-Ming Shi, Yu-Ping Ning, Xin-Hu Yang et al. 21 citations

Objectives The purpose of this systematic review of randomized controlled trials (RCTs) was to evaluate the effectiveness, safety, and tolerability of psilocybin in adult patients with major depressive disorder (MDD). Methods A systematic search (up to September 14, 2023) was conducted for RCTs that examined the efficacy, safety, and tolerability of psilocybin in physically healthy adult...

A comparison of the antianhedonic effects of repeated ketamine infusions in melancholic and non-melancholic depression

Frontiers in Psychiatry December 22, 2022 Wei Zheng, Xin-Hu Yang, Li-Mei Gu et al. 4 citations

ObjectivesMelancholic depression may respond differently to certain treatments. The aim of this study was to compare the antianhedonic effects of six intravenous injections of 0.5 mg/kg ketamine in patients with melancholic and non-melancholic depression, which remain largely unknown.MethodsIndividuals experiencing melancholic (n = 30) and non-melancholic (n = 105) depression were recruited and...